Page 3 - Protara Therapeutics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Protara therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Protara Therapeutics Today - Breaking & Trending Today

Protara Therapeutics Shares Interim Data From Bladder Cancer Study, Raises $45M Via Equity

Friday, Protara Therapeutics Inc (NASDAQ:TARA) shared data from three-month evaluable carcinoma in situ (CIS) patients treated across TARA-002 program, the company’s investigational cell-based therapy, in high-risk Non-Muscle Invasive Bladder Cancer (NMIBC), including Bacillus Calmette-Guérin (BCG)-Unresponsive, BCG-Experienced and BCG-Naïve patient populations. Data were derived from three-month evaluable NMIBC patients with CIS pooled across the company’s ADVANCED-1 Phase 1a, Phase 1b-expansio ....

Protara Therapeutics Inc , Non Muscle Invasive Bladder Cancer , Bacillus Calmette Gu , Protara Therapeutics , Common Warrant , Pre Funded Warrant , Stock Market Game , Benzinga Pro , Day Trial , Via Equity , Bladder Cancer , Protara Therapeutics , Evaluable Patients , Bacillus Calmette Guérin , Choline Chloride ,

Protara Therapeutics Shares Interim Data From Bladder Cancer Study, Raises $45M Via Equity Why Is Protara Therapeutics Stock Trading Lower On Friday? - Protara Therapeutics (NASDAQ:TARA)

Explore TARA-002's data in NMIBC treatment. Discover findings from three trials, including response rates, adverse events, and future plans. Stay updated on Protara Therapeutics' advancements in cancer therapy and FDA alignment for Choline Chloride. ....

Protara Therapeutics , Non Muscle Invasive Bladder Cancer , Bacillus Calmette Gu , Common Warrant , Pre Funded Warrant ,